Shares: Taking Stock
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Parambe could be the vehicle for the next market-bound restaurant chain. The shares rose 16p to 93.5p after the company said it was in talks which could lead to a substantial acquisition.
With restaurant groups queuing to come to market, it is believed Parambe, which had intended to liquidate, has been approached by a well-known eating-out chain.
Its assets consist of paintings and equities and it was due to wind up at the end of 2,000.
KS Biomedix is challenging to become the new biotech star. Suggestions that t is thinking of listing on Nasdaq lifted the shares 27.5p to a 265p peak.
Last month the recent drugs tiddler, which is now worth more than pounds 100m, said it had developed three antibodies for colon cancer.
Other developments are thought to be near to being unveiled. This year the shares have surged from 106p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments